Financial Lp Hrt Acquires 8,266 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 8,266 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was bought at an average cost of $3.38 per share, for a total transaction of $27,939.08. Following the completion of the transaction, the insider directly owned 60,540 shares of the company’s stock, valued at approximately $204,625.20. This trade represents a 15.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Friday, July 10th, Financial Lp Hrt bought 731 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average price of $3.11 per share, with a total value of $2,273.41.
• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt acquired 3,959 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ SHPH traded up $0.21 during trading hours on Monday, reaching $3.13. 55,192 shares of the stock were exchanged, compared to its average volume of 547,562. The firm has a market capitalization of $1.99 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. The stock’s fifty day simple moving average is $5.01 and its 200 day simple moving average is $10.06. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.71 and a 52 week high of $55.90.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SHPH. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the fourth quarter worth about $26,000. Boothbay Fund Management LLC acquired a new stake in Shuttle Pharmaceuticals during the fourth quarter worth about $37,000. Ikarian Capital LLC acquired a new stake in Shuttle Pharmaceuticals during the fourth quarter worth about $124,000. Finally, Connective Capital Management LLC bought a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at about $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Analyst Upgrades and Downgrades

SHPH has been the subject of a number of research reports. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .